Pharmacogenomics in China

Handbook of Pharmacogenomics and Stratified Medicine

Volumn , Issue , 2014, Pages 999-1013

  Zhang, Wei ^a   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a   Chen, Xiao Ping ^a   He, Yi Jing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

China's population; Drug metabolizing enzymes; Herb drug interactions; Ion channels; Pharmacogenomics; Polymorphism; Receptors; Translational medicine; Transporters

Indexed keywords

EID: 84942117103     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386882-4.00044-X     Document Type: Chapter

References (25)

1. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989, 320(9):565-570.
2. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997, 281(1):604-609.
3. Shu Y, Wang LS, Xu ZH, He N, Xiao WM, Wang W, et al. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. J Pharmacol Exp Ther 2000, 295(2):844-851.
4. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999, 66(6):642-646.
5. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005, 353(1-2):187-192.
6. Chen GL, Wang H, Wang W, Xu ZH, Zhou G, He F, et al. Histamine N-methyltransferase gene polymorphisms in Chinese and their relationship with enzyme activity in erythrocytes. Pharmacogenetics 2003, 13(7):389-397.
7. Chen GL, Zhu B, Nie WP, Xu ZH, Tan ZR, Zhou G, et al. Single nucleotide polymorphisms and haplotypes of histamine N-methyltransferase in patients with gastric ulcer. Inflamm Res 2004, 53(9):484-488.
8. Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, Zhou HH, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009, 19(3):206-216.
9. Yin JY, Han LF, Huang Q, Xu XJ, Zhou HH, Liu ZQ ABCC1 polymorphism Arg723Gln (2168G>A) is associated with lung cancer susceptibility in a Chinese population. Clin Exp Pharmacol Physiol 2011, 38(9):632-637.
10. Qu J, Zhou BT, Yin JY, Xu XJ, Zhao YC, Lei GH, et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther 2012, 18(8):647-651.
11. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006, 373(1-2):99-103.
12. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, et al. SLCO1B1 521T>C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 2007, 64(3):346-352.
13. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006, 62(5):567-572.
14. Huang Q, Yin JY, Dai XP, Wu J, Chen X, Deng CS, et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 2010, 66(12):1207-1215.
15. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, et al. Gly389Arg polymorphism of β1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003, 74(4):372-379.
16. Huang Q, Yang TL, Tang BS, Chen X, Huang X, Luo XH, et al. Two novel functional single nucleotide polymorphisms of ADRB3 are associated with type 2 diabetes in the Chinese population. J Clin Endocrinol Metab 2013, 98(7):E1272-E1277.
17. Pei Q, Huang Q, Yang GP, Zhao YC, Yin JY, Song M, et al. PPARγ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China. Acta Pharmacol Sin 2013, 34(2):255-261.
18. Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ, et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 2012, 18(7):566-572.
19. He FZ, Luo J, Luo Z, Fan L, He Y, Zhu D, et al. The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α, β-ADR Blocker Response in EH Patients in China. PLoS One 2013, 8(4):e61317.
20. He FZ, McLeod HL, Zhang W Current pharmacogenomic studies on hERG potassium channels. Trends Mol Med 2013, 19(4):227-238.
21. Dai XP, Huang Q, Yin JY, Guo Y, Gong ZC, Lei MX, et al. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol 2012, 39(5):462-468.
22. Yu M, Xu XJ, Yin JY, Wu J, Chen X, Gong ZC, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2010, 87(3):330-335.
23. Zhou BT, Zhou QH, Yin JY, Li GL, Xu XJ, Qu J, et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin Exp Pharmacol Physiol 2012, 39(4):379-384.
24. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John's Wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004, 75(3):191-197.
25. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2008, 83(3):471-476.